VRN 11
Alternative Names: VRN-11Latest Information Update: 16 Jan 2024
At a glance
- Originator Voronoi
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Non-small cell lung cancer
Most Recent Events
- 16 Jan 2024 Clinical trials in Non-small cell lung cancer in Unknown location (PO) prior to January 2024 (Voronoi pipeline, January 2024)
- 30 Nov 2021 VRN 11 is available for licensing as of 30 Nov 2021. https://voronoi.io/en/company/about-voronoi/
- 29 Nov 2021 Preclinical trials in Non-small cell lung cancer in South Korea (PO) (Voronoi pipeline, November 2021)